Preclinical Efficacy of the Combination of Met and Src Family Kinase Inhibitors in Triple-Negative Breast Cancer.

被引：0
|
作者：
Gartner, E. M. [1 ]
Kim, E. M. H. [1 ]
Choi, L. [1 ]
Boerner, J. [1 ]
机构：
[1] Wayne State Univ, Karmanos Canc Ctr, Detroit, MI USA
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/0008-5472.SABCS11-P008-08
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD08-08
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Preclinical efficacy of the combination of olaparib plus carboplatin with vandetanib in triple-negative breast cancer.
    Dey, Nandini
    Wu, Hui
    Sun, Yuliang
    De, Pradip
    Leyland-Jones, Brian
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] Preclinical studies with neratinib in triple-negative breast cancer.
    Mulloly, Maeve
    O'Brien, Neil A.
    Conklin, Dylan
    Finn, Richard S.
    Slamon, Dennis J.
    Crown, John
    O'Donovan, Norma
    McGowan, Patricia M.
    Duffy, Michael J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] Novel synergistic combination therapies with BET bromodomain inhibitors in triple-negative breast cancer.
    Bevill, Samantha M.
    Sciaky, Noah
    Golitz, Brian T.
    Rashid, Naim U.
    Zawistowski, Jon S.
    Johnson, Gary L.
    [J]. MOLECULAR CANCER RESEARCH, 2018, 16 (08) : 80 - 80
  • [4] Significance of the combination of biguanides and fatty acid β-oxidation inhibitors in triple-negative breast cancer.
    Park, Junhyoung
    Jung, Kwang Hwa
    Jia, Dongya
    Yang, Sukjin
    Sakthivel, Dharaniya
    Tiwari, Abha
    Onuchic, Jose N.
    Kaipparettu, Benny Abraham
    [J]. CANCER RESEARCH, 2021, 81 (13)
  • [5] Preclinical antitumor activity of novel small molecule glutaminase inhibitors in triple-negative breast cancer.
    Demo, Susan
    Chernov-Rogan, Tania
    Gross, Matthew
    Janes, Julie
    Kawas, Raja
    Lewis, Evan
    Parlati, Francesco
    Rodriguez, Hector
    Rodriguez, Mirna
    Yang, Jinfu
    Zhao, Frances
    Richardson, Adam
    Bennett, Mark K.
    [J]. CANCER RESEARCH, 2013, 73 (08)
  • [6] Rational combination of mTOR and Aurora kinase A inhibition in preclinical models of triple-negative breast cancer
    Diamond, Jennifer R.
    Orth, James D.
    Ionkina, Anastasia
    Dailey, Kyrie
    Pitts, Todd M.
    Capasso, Anna
    Marcus, Joshua M.
    Burke, Russell T.
    Davis, Sarah L.
    Kim, Jiyhe
    Tan, Aik-Choon
    Eckhardt, Sue G.
    Tentler, John J.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [7] C-src: A potential target for the treatment of triple-negative breast cancer.
    Walsh, S.
    Tryfonopoulos, D.
    Quinn, C.
    Flanagan, L.
    Pierce, A.
    McDermott, E.
    Evoy, D.
    O'Donovan, N.
    Crown, J.
    Duffy, M. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [8] Combination Therapies to Improve the Efficacy of Immunotherapy in Triple-negative Breast Cancer
    Aleckovic, Masa
    Li, Zheqi
    Zhou, Ningxuan
    Qiu, Xintao
    Lulseged, Bethlehem
    Foidart, Pierre
    Huang, Xiao-Yun
    Garza, Kodie
    Shu, Shaokun
    Kesten, Nikolas
    Li, Rong
    Lim, Klothilda
    Garrido-Castro, Ana C.
    Guerriero, Jennifer L.
    Qi, Jun
    Long, Henry W.
    Polyak, Kornelia
    [J]. MOLECULAR CANCER THERAPEUTICS, 2023, 22 (11) : 1304 - 1318
  • [9] Triple-negative Breast Cancer: Identification of circRNAs With Efficacy in Preclinical In Vivo Models
    Weidle, Ulrich H.
    Birzele, Fabian
    [J]. CANCER GENOMICS & PROTEOMICS, 2023, 20 (02) : 117 - 131
  • [10] Epigenetic heterogeneity in triple-negative breast cancer.
    Maruyama, Reo
    Yang, Liying
    Kumegawa, Kohei
    [J]. MOLECULAR CANCER RESEARCH, 2018, 16 (08) : 29 - 30
12345